...
首页> 外文期刊>American Journal of Perinatology >Correlation of maternal and fetal hepatitis B antibody titers following maternal vaccination in pregnancy.
【24h】

Correlation of maternal and fetal hepatitis B antibody titers following maternal vaccination in pregnancy.

机译:孕产妇接种疫苗后母婴乙型肝炎抗体滴度的相关性。

获取原文
获取原文并翻译 | 示例

摘要

The objective of this study was to compare the levels of hepatitis B antibody in maternal and cord blood following maternal vaccination in pregnancy and to determine the level of maternal hepatitis B surface antibody (HbsAb) associated with a seroprotective level in cord blood. Thirty-seven (37) healthy gravidas who were identified as seronegative for hepatitis B surface antigen (HbsAg) and antibody (HbsAb) on initial prenatal assessment and subsequently began a series of three vaccinations in the pregnancy with hepatitis B recombinant DNA vaccine (Engerix-B, SmithKline Beecham) were studied. These mothers represented the first group of gravidas delivering between 6/1/97 and 8/1/97 following the iniatiation of a new protocol of offering hepatitis B vaccination to all patients testing seronegative to HbsAg and HbsAb. All gravidas were given a dose of 20 microg into the deltoid muscle utilizing a 1 1/2-inch needle at a schedule of 0, 1, and 6 months. At the time of delivery specimens were obtained for maternal serum levels and paired cord blood levels of HbsAb. Levels were determined utilizing a quantitative enzyme-linked immunoadsorbent assay (ELISA) analysis (AUSAB-EIA Abbott Lab; Abbott Park, IL). A serum titer of > or =10 mLU/mL was considered seroprotective. Maternal and cord blood groups identified by seroprotection status were then sudivided by number of maternal vaccines received. Data were compared using the Student's t-test and Chi-square or Fisher's exact test. Eighteen gravidas (49%) had seroprotective titers at the time of delivery. Of these, 16 (88%) had seroprotective cord blood levels. All maternal specimens with a HbsAb titer > or =35 mLU/mL were associated with cord blood tiers > or =10 mLU/mL. When maternal titers achieved seroprotective levels of HbsAb, there was no difference in the frequency of cord blood seroprotection comparing groups by number of maternal vaccine doses received. When maternal titers of HbsAb achieve seroprotective levels following vaccination, cord blood seroprotection was achieved in 88% of studied patients. Maternal HbsAb titers > or =35 mLU/mL were associated with cord blood seroprotective levels in all cases.
机译:这项研究的目的是比较孕妇接种疫苗后母体和脐带血中的乙型肝炎抗体水平,并确定与脐带血中的血清保护水平相关的母体乙型肝炎表面抗体(HbsAb)水平。三十七(37)名健康孕妇在产前评估中被确认为乙肝表面抗原(HbsAg)和抗体(HbsAb)的血清反应阴性,随后在怀孕期间开始使用乙肝重组DNA疫苗(Engerix- B,SmithKline Beecham)进行了研究。这些母亲是第一批在6/1/97至8/1/97分娩的孕妇,在新方案开始后向所有检测HbsAg和HbsAb血清反应阴性的患者提供乙肝疫苗接种。使用1 1/2英寸的针头,在0、1、6个月的时间表中,将所有的孕妇的三角肌肌肉注射20微克。在分娩时,获得了母体血清水平和成对的脐血HbsAb水平的标本。使用定量酶联免疫吸附测定(ELISA)分析(AUSAB-EIA雅培实验室;艾伯特公园,伊利诺伊州)确定水平。大于或等于10 mLU / mL的血清滴度被认为是血清保护性的。然后根据接受的母体疫苗的数量对通过血清保护状态鉴定的母体和脐带血型进行汇总。使用学生t检验和卡方检验或Fisher精确检验比较数据。分娩时有十八个孕妇(49%)具有血清保护滴度。其中16(88%)人具有血清保护性脐带血水平。 HbsAb滴度≥35 mLU / mL的所有孕妇标本均与脐血> 10 mLU / mL或更高。当母体效价达到HbsAb的血清保护水平时,脐带血血清保护比较组的频率在接受母体疫苗剂量方面没有差异。疫苗接种后,当母体滴度的HbsAb达到血清保护水平时,88%的研究患者达到了脐带血血清保护。在所有情况下,母体HbsAb滴度≥35 mLU / mL均与脐带血血清保护水平有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号